ischemic heart

JTV-519 is a Ca2+-dependent blocker and prevents abnormal Ca(2+) leak from the sarcoplasmic reticulum in the ischemic heart and skeletal muscle (SkM) by stabilizing the ryanodine receptors.

Afacifenacin (SMP-986) fumarate is an M3 muscarinic receptor-selective antagonist used in the study of ischemic heart disease, urinary incontinence and cystitis and other disorders.

Nebivolol hydrochloride (R 065824 hydrochloride) is a cardioselective ADRENERGIC BETA-1 RECEPTOR ANTAGONIST (beta-blocker) that functions as a VASODILATOR through the endothelial L-arginine NITRIC OXIDE system. It is used to manage HYPERTENSION and chronic HEART FAILURE in elderly patients.

Trimetazidine dihydrochloride (Vastarel F) can improve myocardial glucose utilization by inhibiting fatty acid metabolism. Trimetazidine is the first cytoprotective anti-ischemic agent, also used as a vasodilator in ischemic heart disease or angina.

Aplodan (creatinol-O-phosphate) exhibits antiischemic and antiarrhythmic capacity and protective action on the cell membrane. Aplodan can be used in research on the ischemic heart or ischemic heart disease with persistent ventricular premature beats.

Sodium Hydrogen Sulfide (hydrate) is, like nitric oxide, an important gaseous mediator that has significant effects on the immunological, neurological, cardiovascular and pulmonary systems of mammals. Sodium Hydrogen Sulfide (hydrate) is an H2S donor commonly used in cellular and whole animal experimental systems. For example, it has been used to suggest that H2S promotes neutrophil migration, reduces airway inflammation, and protects neurites, heart, and intestine from chemical or ischemic-reperfusion damage.

Trapidil (Avantrin) is a coronary vasodilator agent. It was originally developed as a vasodilator and anti-platelet agent and has been used to treat patients with ischemic coronary heart, liver, and kidney disease.

KR-32568 is a sodium hydrogen exchanger 1 (NHE-1) inhibitor (IC50: 230 nM) with potent cardioprotective effects. At a concentration of 10 μM, it restored cardiac systolic function in an isolated ischemic rat heart model. Additionally, KR-32568 (0.3 mg kg) reduced myocardial infarction size in a rat model of ischemia and reperfusion injury.

Levocarnitine propionate (L-Propionylcarnitine) is a propionyl-coenzyme A (Pro-CoA) derivative with anti-ischemic effects and high affinity for muscle L-carnitine transferase. Levocarnitine propionate enhances substrate oxidation and mitochondrial respiration in the heart of diabetic rats, reduces gastric ulcer area, induces mucosal recovery, and can be used to study acute respiratory distress syndrome and chronic gastric ulcers in Alzheimer's disease.

BRL 52537 hydrochloride is a selective and specific KOR agonist which has been implicated in neuroprotection from ischemic neuronal injury[1]. It is used for research into potential treatments for stroke and heart attack as well as more general brain rese

MMPSI (Caspase-3 7 Inhibitor I) is a novel, non-peptide small molecule caspase 3 and caspase 7 inhibitor that reduces ischemic injury in isolated rabbit heart or cardiomyocytes and inhibits apoptosis of H16c2 cells in a concentration-dependent manner.MMPSI can be used to study cardioprotection and myocardial injury.

GSK854 is a highly selective and potent inhibitor of troponin I interacting kinase (TNNI3K) that inhibits myocardial infarction-injured cellular pyroptosis and apoptosis in mice, which may limit oxidative stress, injury, and adverse remodeling in the ischemic heart.

Tiracizine HCl, a new class I antiarrhythmic drug, was studied in patients with ischemic heart disease and shown to decrease myocardial contractile function.

FR-168888, a new Na+ H+ exchange inhibitor, can protect the heart from arrhythmia and myocardial cell death in ischemic and reperfused situations.

Nirudipine is a double (2-propoxyethyl) analogist of nifedipine and a calcium channel blocker, which is also a safe anti-angina Ca2+ antagonist with a broad range of efficacy for all types of angina. At the same time, Niludipine is a highly effective drug

(±)14(15)-EET is a metabolite of arachidonic acid that is formed via epoxidation of arachidonic acid by cytochrome P450.[1],[2] It prevents increases in leukotriene B4, ICAM-1, and chemokine (C-C motif) ligand 1 (CCL2) induced by oxidized LDL in primary rat pulmonary artery endothelial cells (RPAECs) when used at a concentration of 1 μM.[3] (±)14(15)-EET induces dilation of preconstricted isolated canine coronary arterioles (EC50 = 0.2 pM).[4] It reduces myocardial infarct size as a percentage of the area at risk in a canine model of ischemia-reperfusion injury induced by left anterior descending coronary artery (LAD) occlusion when administered at a dose of 0.128 mg kg prior to occlusion or reperfusion.[5] Reference:[1]. Chacos, N., Falck, J.R., Wixtrom, C., et al. Novel epoxides formed during the liver cytochrome P-450 oxidation of arachidonic acid. Biochem. Biophys. Res. Commun. 104(3), 916-922 (1982).[2]. Oliw, E.H., Guengerich, F.P., and Oates, J.A. Oxygenation of arachidonic acid by hepatic monooxygenases. Isolation and metabolism of four epoxide intermediates. J. Biol. Chem. 257(7), 3771-3781 (1982).[3]. Jiang, J.-X., Zhang, S.-J., Xiong, Y.-K., et al. EETs attenuate ox-LDL-induced LTB4 production and activity by inhibiting p38 MAPK phosphorylation and 5-LO BLT1 receptor expression in rat pulmonary arterial endothelial cells. PLoS One 10(6), e0128278 (2015).[4]. Oltman, C.L., Weintraub, N.L., VanRollins, M., et al. Epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids are potent vasodilators in the canine coronary microcirculation. Circ. Res. 83(9), 932-939 (1998).[5]. Nithipatikom, K., Moore, J.M., Isbell, M.A., et al. Epoxyeicosatrienoic acids in cardioprotection: Ischemic versus reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 291(2), H537-H542 (2006).

L-Palmitoylcarnitine chloride (Palmitoyl-L-carnitine chloride) is a fatty acid metabolite with antithrombotic properties that protects mice from ischemic stroke by counteracting intracerebral thrombosis in the tMCAO model.L-Palmitoylcarnitine chloride (Palmitoyl-L-carnitine chloride) is a fatty acid metabolite with antithrombotic properties. Palmitoylcarnitine chloride inhibits the Na K pump in the heart and inhibits FeCl 3-induced arterial thrombosis Attenuates intracerebral thrombosis and inflammation in a mouse model of transient middle cerebral artery occlusion (tMCAO).

1. Ginsenoside Rk3 and Rh4 could have a role in treating inflammatory diseases. 2. Ginsenoside Rk3 is often used as a major ingredient of the compound preparation for ischemic heart diseases.

FR-168888 free base is a new Na+ H+ exchange inhibitor. FR-168888 has a strong inhibitory effect on Na+ H+ exchange and has been shown to protect the heart from arrhythmia and myocardial cell death in ischemic and reperfused situations.

Palmitoyl L-Carnitine-d3 Hydrochloride is a deuterated compound of Palmitoyl L-Carnitine Hydrochloride. Palmitoyl L-Carnitine Hydrochloride has a CAS number of 18877-64-0. L-Palmitoylcarnitine chloride (Palmitoyl-L-carnitine chloride) is a fatty acid metabolite with antithrombotic properties that protects mice from ischemic stroke by counteracting intracerebral thrombosis in the tMCAO model.L-Palmitoylcarnitine chloride (Palmitoyl-L-carnitine chloride) is a fatty acid metabolite with antithrombotic properties. Palmitoylcarnitine chloride inhibits the Na K pump in the heart and inhibits FeCl 3-induced arterial thrombosis Attenuates intracerebral thrombosis and inflammation in a mouse model of transient middle cerebral artery occlusion (tMCAO).

Trimetazidine-d8 Dihydrochloride is a deuterated compound of Trimetazidine Dihydrochloride. Trimetazidine Dihydrochloride has a CAS number of 13171-25-0. Trimetazidine dihydrochloride can improve myocardial glucose utilization by inhibiting fatty acid metabolism. Trimetazidine is the first cytoprotective anti-ischemic agent, also used as a vasodilator in ischemic heart disease or angina.

Astringinin is a potent antiarrhythmic agent with cardioprotective activity in ischemic and ischemic-reperfused rat heart, the beneficial effects of astringinin in the ischemic and ischemic-reperfused hearts may be correlated with its antioxidant activity and upregulation of NO production.